Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, MD, Maria-Theresa Krauth, MD, Alexander Gruze, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 1437.

https://doi.org/10.1182/blood.V108.11.1437.1437

Published: 2006

Journal Articles

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412

Karl J. Aichberger, Matthias Mayerhofer, Karoline V. Gleixner, Maria-Theresa Krauth, Alexander Gruze, Winfried F. Pickl, Volker Wacheck, Edgar Selzer, Leonhard Müllauer, Hermine Agis, Christian Sillaber, Peter Valent

Blood (2006) 109 (7): 3031–3041.

https://doi.org/10.1182/blood-2006-07-032714

Published: 2006

Journal Articles

Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Anna Vales, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Edgar Selzer, MD, Michael Deininger, MD, PhD, Brian J. Druker, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 1987.

https://doi.org/10.1182/blood.V106.11.1987.1987

Published: 2005

Journal Articles

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Hermine Agis, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 3516.

https://doi.org/10.1182/blood.V106.11.3516.3516

Published: 2005

Journal Articles

The Target Receptor Siglec-3 (CD33) Is Expressed on AML Stem Cells in a Majority of All Patients with AML.

Alexander W. Hauswirth, MD, Stefan FLorian, MD, Maria-Theresa Krauth, MD, Gerit-Holger Schernthaner, MD, Edgar Selzer, MD, Volker Wacheck, MD, Dieter Printz, Gerhard Fritsch, MD, Karl Sotlar, MD, Wolfgang R. Sperr, MD, Peter Valent, MD

Blood (2005) 106 (11): 4324.

https://doi.org/10.1182/blood.V106.11.4324.4324

Published: 2005

Journal Articles

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides

Karl J. Aichberger, Matthias Mayerhofer, Maria-Theresa Krauth, Hans Skvara, Stefan Florian, Karoline Sonneck, Cahit Akgul, Sophia Derdak, Winfried F. Pickl, Volker Wacheck, Edgar Selzer, Brett P. Monia, Richard Moriggl, Peter Valent, Christian Sillaber

Blood (2005) 105 (8): 3303–3311.

https://doi.org/10.1182/blood-2004-02-0749

Published: 2005

Journal Articles

Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.

Karl J. Aichberger, MD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Hans Skvara, MD, Stefan Florian, MD, Karoline Sonneck, MD, Cahit Akgul, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Brett P. Monia, PhD, Richard Moriggl, PhD, Peter Valent, MD, Christian Sillaber, MD

Blood (2004) 104 (11): 2972.

https://doi.org/10.1182/blood.V104.11.2972.2972

Published: 2004

Journal Articles

The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.

Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Stefan Florian, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Harald Esterbauer, PhD, MD, Oswald Wagner, MD, Winfried F. Pickl, MD, Edgar Selzer, MD, Michael W. Deininger, PhD, MD, Brian J. Druker, MD, Khaled Greish, PhD, Hiroshi Maeda, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2004) 104 (11): 1986.

https://doi.org/10.1182/blood.V104.11.1986.1986

Published: 2004

Journal Articles

The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade

Peter Blaha, Sinda Bigenzahn, Zvonimir Koporc, Maximilian Schmid, Felix Langer, Edgar Selzer, Helga Bergmeister, Friedrich Wrba, Josef Kurtz, Christopher Kiss, Erich Roth, Ferdinand Muehlbacher, Megan Sykes, Thomas Wekerle

Blood (2003) 101 (7): 2886–2893.

https://doi.org/10.1182/blood-2002-10-3014

Published: 2003

NARROW

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412

Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

The Target Receptor Siglec-3 (CD33) Is Expressed on AML Stem Cells in a Majority of All Patients with AML.

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides

Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.

The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.

The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only